Ubs Group Ag Lian Bio Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.33 - $4.6 $5,850 - $20,235	4,399 New	4,399 $19,000
Q2 2023 Aug 11, 2023	BUY	$1.79 - $2.85 $179 - $285	100 New	100 $0
Q4 2022 Feb 08, 2023	BUY	$1.14 - $2.11 $3,165 - $5,859	2,777 Added 222.69%	4,024 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.87 - $3.0 $2,331 - $3,741	1,247 New	1,247 $2,000
Q2 2022 Aug 10, 2022	SELL	$2.15 - $6.01 $72,005 - $201,280	-33,491 Closed	0 $0

Q1 2022 May 16, 2022	BUY	$2.8 - $6.21 $93,774 - $207,979	33,491 New	33,491 $124,000

1.09M

Ticker LIAN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,354,000
Market Cap $32.5M
Description
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with p...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.